CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy: These findings highlight the need for personalized immunotherapy based on serological profiles and highlight the potential value of early anti-CNTN1 antibody detection as a prognostic and therapeutic marker in CIDP-MN cases.